Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Humacyte, Inc. (HUMA)

Humacyte Adds Scott Coward and Paul Kuznik to Board of Directors

Neutral Impact 2 of 5 leadership Written later

Humacyte appointed two new directors, Scott Coward and Paul Kuznik, effective September 22, 2026, and announced the appointments in a September 28, 2026 press release. Mr. Coward joins the Audit Committee and Mr. Kuznik joins the Commercial Committee, and both will receive standard non-employee director compensation. The filing reports no financial results and no change in management roles, so the change has limited direct impact on shareholders.

Key points

  • Scott Coward appointed Class I director with a term expiring in 2028; former Exact Sciences executive and board member
  • Paul Kuznik appointed Class II director with a term expiring in 2029; former CEO of Bolton Medical
  • Each director receives a $50,000 annual cash retainer, $5,000 per year for committee service, and an option to purchase 125,000 shares of common stock

The filing

CompanyHumacyte, Inc. (HUMA)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:05 PM ET
Accession number0001818382-26-000011

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.